Medicine has used hyperbaric oxygen therapy, or HBOT, for more than 40 years and we still don’t know if it works and for what conditions. Many doctors are using it to cure chronic diabetic foot ulcers that otherwise often lead to amputation. Since these ulcers are a common complication of diabetes and loss of a foot has such a drastic impact on the quality of life, HBOT is something that some people think we should use.
I’ve been convinced that the use of hyperbaric oxygen might offer many benefits ever since I visited an 82-year-old man named John Erb in Costa Rica two years ago. He is an expatriate American who took me inside his hyperbaric oxygen chamber and showed me to what he attributes his strength. I took the photo below, as I wrote in my photo essay “Rancho Naturalista,” the ecolodge that he owns.
(Only in My Photo Did He Lose His Feet)
HBOT is widely available in North America where we have more than 300 registered facilities. It’s typically 15 to 30 sessions of one to two hours where you breath concentrated oxygen at a higher than usual pressure.
But the use of HBOT for chronic foot ulcers remains controversial. Its use in diabetic foot care was the principal focus of a “great debate” that the American Diabetes Association sponsored at its annual convention in Boston this month. The subject was important enough that along with thousands of medical professionals I listened to experts debate the question at an early morning session that marked the highlight of my third day there.
Speaking in favor of using HBOT to cure diabetic foot ulcers was its outspoken proponent and lead author of the best study, Magnus Löndahl, MD, PhD, of Sweden’s Lund University. Debating him was Ludwik Fedorko, MD, PhD, of Toronto General Hospital. He hasn’t published any HBOT studies, but is one of the researchers conducting a study in progress.
The Cochrane Collaboration Review
Dr. Löndahl’s main challenge was to address the Cochrane Collaboration’s review of “Hyperbaric oxygen therapy for chronic wounds.” It reviewed all nine randomized controlled trials of HBOT and concluded that, “In people with foot ulcers due to diabetes, HBOT significantly improved the ulcers healed in the short term but not the long term, and the trials had various flaws in design and/or reporting that means we are not confident in the results.” But, Dr. Löndahl says, that this is misleading and recommends that we read the entire paper.
It’s available free online, and I have read all of its 63 pages and agree with him. It’s clear from the review’s “methodological quality summary” that the study led by Dr. Löndahl, “Hyperbaric Oxygen Therapy Facilitates Healing of Chronic Foot Ulcers in Patients With Diabetes” in the May 2010 issue of Diabetes Care, meets the highest standard of these studies. This double-blinded, randomized, placebo-controlled trial showed that people with diabetes who had chronic foot ulcers healed at least twice the rate of people in the placebo arm at every time interval up to the 12 months of the study.
HBOT Is Expensive
Dr. Fedorko argued that HBOT “is very costly, competing for resources and time” with other treatments, which of course include surgery. “Diabetes is a disease of the blood vessels, and foot ulcers are no different. The only way to make them disappear is to improve glucose control.”
In the United States a full course of HBOT costs between $50,000 and $200,000. Obviously, that’s beyond the reach of almost all of us, unless our health insurance covers it.
If it is covered, I agree with Dave Joffe, the editor-in-chief of “Diabetes in Control,” the largest diabetes Internet website and newsletter for medical professionals. Dave is a pharmacist and Certified Diabetes Educator, and I interviewed him at the Boston meeting.
He suggests that if you have a diabetic foot ulcer, “Why not try this therapy?” I agree. The likely alternative is the loss of your ulcerated foot.
See more of my articles about how to manage diabetes:
David Mendosa was a journalist who learned in 1994 that he had type 2 diabetes, which he wrote about exclusively. He died in May 2017 after a short illness unrelated to diabetes. He wrote thousands of diabetes articles, two books about it, created one of the first diabetes websites, and published a monthly newsletter, “Diabetes Update.” His very low-carbohydrate diet, A1C level of 5.3, and BMI of 19.8 kept his diabetes in remission without any drugs until his death.